Advanced Technology International (ATI) has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to serve as the consortium manager for the new Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The consortium aims to improve and expand the industrial and manufacturing base for medical countermeasures during public health emergencies. The BioMaP-Consortium is made up of industry partners across the drug and vaccine manufacturing supply chain. They will work together to accelerate the development and delivery of medical countermeasures.
ATI has been selected to manage the BARDA Biopharmaceutical Manufacturing Preparedness Consortium. As the consortium manager, ATI will work with industry partners to expand the industrial and manufacturing base for medical countermeasures during public health emergencies. The BioMaP-Consortium will focus on accelerating the development and delivery of these medical countermeasures. ATI has been awarded an Other Transaction (OT) Agreement by BARDA, part of the U.S. Department of Health and Human Services (HHS), to serve as the consortium manager for the new 10-year BioMaP-Consortium.
The BioMaP-Consortium is made up of industry partners across the drug and vaccine manufacturing supply chain. Members of the consortium include manufacturers of raw materials, consumables, and drug substances, as well as suppliers of fill finish services and innovators in manufacturing technologies. These industry partners will work together to address the challenges of manufacturing medical countermeasures during public health emergencies and to accelerate the development and delivery of these products.
ATI is a public-service nonprofit organization based in Summerville, South Carolina. The organization builds and manages collaborations that conduct research and development of new capabilities to solve the nation’s most challenging problems. ATI works with a community of experts from industry, academia, and government to expedite innovation and help the federal government identify and acquire novel technologies and solutions. ATI’s mission is to provide the federal government with innovative solutions to the nation’s most pressing challenges. By identifying and developing new capabilities, ATI helps to strengthen the country’s security and improve the quality of life for all Americans.
The BioMaP-Consortium is a 10-year initiative aimed at improving and expanding the industrial and manufacturing base for medical countermeasures during public health emergencies. The consortium will focus on accelerating the development and delivery of these lifesaving products. The goal of the BioMaP-Consortium is to enhance the nation’s preparedness and response capabilities by ensuring a robust and flexible medical countermeasure manufacturing infrastructure. This infrastructure will enable the rapid development, production, and delivery of medical countermeasures in response to public health emergencies, such as pandemics and bioterrorist attacks.
The BioMaP-Consortium will bring together industry partners from across the drug and vaccine manufacturing supply chain, including raw material suppliers, drug substance manufacturers, fill finish service providers, and developers of innovative manufacturing technologies. Through collaboration and coordination, the consortium aims to address the challenges of manufacturing medical countermeasures in a timely and efficient manner. By working together, the consortium members will be able to leverage their collective expertise and resources to develop new technologies, improve manufacturing processes, and enhance the capacity and capability of the overall manufacturing base.
ATI is honored to have been selected as the consortium manager for the BioMaP-Consortium. The organization is committed to supporting BARDA in its mission to enhance the nation’s health security and strengthen its preparedness and response capabilities. ATI will work closely with its industry partners to expedite the development and delivery of medical countermeasures and ensure the robustness and flexibility of the nation’s medical countermeasure manufacturing infrastructure. With ATI’s experience and expertise in managing collaborations and accelerating innovation, the BioMaP-Consortium is well positioned to make significant contributions to the nation’s preparedness and response efforts.
The BioMaP-Consortium is funded by the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number #75A50123D00003.